The global market for hospital clinical chemistry and immunodiagnostics is examined in a recent market research report by Transparency Market Research. The report, titled “Hospital Clinical Chemistry and Immunodiagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” analyzes the market on the basis of key segments, geographies, and trends.
The market has witnessed vast advances in the past few years, resulting in the development of diagnostic technologies such as spectrophotometry, molecular diagnostics, measurement of enzyme activities, electrophoresis, and separation of molecules. Developments across these specialty segments have significantly changed the way and the extent to which clinicians can diagnose, prevent, and treat a variety of diseases.
Download Free PDF brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6925
Diseases that are generally diagnosed with the help of clinical chemistry include diabetes, viral and bacterial infections, thyroid issues, cardiovascular conditions, and cystic fibrosis in newborn babies.
The varieties of tests that come under the purview of immunodiagnostics include Enzyme-Linked Immuno Sorbent Assay or ELISA and radioimmunoassay. Hospital clinical chemistry includes tests undertaken in the fields such as routine chemistry, endocrinology, drug monitoring, special chemistry, toxicology, and urinalysis.
The report analyzes detailed market data for these end-use segments of the global hospital clinical chemistry and immunodiagnostics market across key geographies, gathering qualitative and quantitative information elucidating the past, present, and the potential future state of these segments. For ease of understanding, the global market is covered by segmenting it into geographical markets such as North America, Asia Pacific, Europe, and Rest of the World.
The market has reached maturity in developed regions such as Europe and North America. Factors supporting growth of these regional markets include the easy availability of advanced and innovative medical technologies across healthcare settings, presence of some of world’s largest healthcare companies, and vast investments towards research and development activities. The vast rise in global prevalence of a number of infectious and chronic diseases has also led to the increased demand for a variety of reliable and advanced diagnostic tests, thus driving the market.
Developments in the field have also resulted in significant reduction in the complexity and duration of immunoassays, thereby bolstering market’s future growth prospects. Asia Pacific is a highly lucrative regional market for clinical chemistry and immunodiagnostics owing to the presence of a large patient pool and rising healthcare expenditures.
Factors such as advancements in diagnostic modalities, intense competition, and automation are leading to the development of vast growth opportunities. Some of the key vendors operating in the market are F. Hoffmann-La Roche Ltd., Abbott, Danaher Corporation, Siemens AG, Bio-Rad Laboratories, Inc., and Thermo Fisher Scientific, Inc.